Last updated on March 2016

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven PhaseIII study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease insubjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease


Brief description of study

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven PhaseIII study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease insubjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

Detailed Study Description

Demonstrate whether finerenone is superior to placebo in delaying the progression of kidney disease. Randomized at 1:1 ratio. Subjects will take one pill once a day.

Clinical Study Identifier: TX143053

Contact Investigators or Research Sites near you

Start Over

Amanda Davis LPN

Chase Medical Research LLC
Waterbury, CT USA
  Connect »